Study Points to Efficacy of Convalescent Plasma for Covid-19

Ref: The Wall Street Journal
  • A study, posted on the Medrxiv public server on Friday, of hospitalized patients with COVID-19 infections provided a sign that blood plasma transfusions from recovered patients may improve survival rates, reported The Wall Street Journal.

  • The research compared 39 coronavirus patients who received convalescent plasma transfusions with similar, matched patients who did not, all at Mount Sinai Hospital in New York during the same 16-day period.

  • Fourteen days after the transfusion, the plasma patients' oxygen requirements stayed the same or improved, and they had improved survival rates compared with the control group, the study found.

  • On the day of the transfusion, the authors noted that most of the patients who received plasma required oxygen and four needed mechanical ventilation. By day 14, the condition of 18% of the patients who received the convalescent plasma had worsened, compared with 24.3% in the matched control group.

  • Further, they said that as of May 1, 12.8% of the plasma recipients had died compared with 24.4% of the control patients, adding that "overall, we observed improved survival for the plasma group."

  • Another finding was there did not appear to be significant benefit in patients who were intubated, but because the number of patients on ventilators in the study was small, researchers were unable to draw definitive conclusions.